Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy

Tewodros Shibabaw Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, EthiopiaCorrespondence: Tewodros ShibabawDepartment of Biochemistry, School of Medicine, University of Gondar, P.O. Box 196, Gondar, EthiopiaTel +251910162171Email...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Shibabaw T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	il-17a inflammation immunopathology covid-19 cytokine storm th17 il-6 ards Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/55001c93c91743d5a504a9750685497b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:55001c93c91743d5a504a9750685497b
record_format	dspace
spelling	oai:doaj.org-article:55001c93c91743d5a504a9750685497b2021-12-02T12:59:32ZInflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy1178-7031https://doaj.org/article/55001c93c91743d5a504a9750685497b2020-10-01T00:00:00Zhttps://www.dovepress.com/inflammatory-cytokine-il-17a-signaling-pathway-in-patients-present-wit-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Tewodros Shibabaw Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, EthiopiaCorrespondence: Tewodros ShibabawDepartment of Biochemistry, School of Medicine, University of Gondar, P.O. Box 196, Gondar, EthiopiaTel +251910162171Email shitewodros@gmail.comAbstract: Coronavirus disease 2019 (COVID-19) is a globally communicable public health disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV-2). Eradication of COVID-19 appears practically impossible but, therefore, more effective pharmacotherapy is needed. The deteriorated clinical presentation of patients with COVID-19 is mainly associated with hypercytokinemia due to notoriously elevated pro-inflammatory cytokines such as interleukin (IL)-1B, IL-6, IL-8, IL-17, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), interferon-γ-inducible protein (IP10), monocyte chemoattractant protein (MCP1), and tumor necrosis factor-α (TNFα), and is usually responsible for cytokine release syndrome. In the cytokine storm, up-regulation of T-helper 17 cell cytokine IL-17A, and maybe also IL-17F, is mostly responsible for the immunopathology of COVID-19 and acute respiratory distress syndrome. Herein, I meticulously review the exuberant polarization mechanism of naïve CD4+ T cells toward Th17 cells in response to SARS-CoV-2 infection and its associated immunopathological sequelae. I also, propose, for clinical benefit, targeting IL-17A signaling and the synergic inflammatory cytokine IL-6 to manage COVID-19 patients, particularly those presenting with cytokine storm syndrome.Keywords: IL-17A, inflammation, immunopathology, COVID-19, cytokine storm, Th17, IL-6, ARDSShibabaw TDove Medical Pressarticleil-17ainflammationimmunopathologycovid-19cytokine stormth17il-6ardsPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 13, Pp 673-680 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	il-17a inflammation immunopathology covid-19 cytokine storm th17 il-6 ards Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	il-17a inflammation immunopathology covid-19 cytokine storm th17 il-6 ards Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Shibabaw T Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy
description	Tewodros Shibabaw Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, EthiopiaCorrespondence: Tewodros ShibabawDepartment of Biochemistry, School of Medicine, University of Gondar, P.O. Box 196, Gondar, EthiopiaTel +251910162171Email shitewodros@gmail.comAbstract: Coronavirus disease 2019 (COVID-19) is a globally communicable public health disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV-2). Eradication of COVID-19 appears practically impossible but, therefore, more effective pharmacotherapy is needed. The deteriorated clinical presentation of patients with COVID-19 is mainly associated with hypercytokinemia due to notoriously elevated pro-inflammatory cytokines such as interleukin (IL)-1B, IL-6, IL-8, IL-17, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), interferon-γ-inducible protein (IP10), monocyte chemoattractant protein (MCP1), and tumor necrosis factor-α (TNFα), and is usually responsible for cytokine release syndrome. In the cytokine storm, up-regulation of T-helper 17 cell cytokine IL-17A, and maybe also IL-17F, is mostly responsible for the immunopathology of COVID-19 and acute respiratory distress syndrome. Herein, I meticulously review the exuberant polarization mechanism of naïve CD4+ T cells toward Th17 cells in response to SARS-CoV-2 infection and its associated immunopathological sequelae. I also, propose, for clinical benefit, targeting IL-17A signaling and the synergic inflammatory cytokine IL-6 to manage COVID-19 patients, particularly those presenting with cytokine storm syndrome.Keywords: IL-17A, inflammation, immunopathology, COVID-19, cytokine storm, Th17, IL-6, ARDS
format	article
author	Shibabaw T
author_facet	Shibabaw T
author_sort	Shibabaw T
title	Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy
title_short	Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy
title_full	Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy
title_fullStr	Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy
title_full_unstemmed	Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy
title_sort	inflammatory cytokine: il-17a signaling pathway in patients present with covid-19 and current treatment strategy
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/55001c93c91743d5a504a9750685497b
work_keys_str_mv	AT shibabawt inflammatorycytokineil17asignalingpathwayinpatientspresentwithcovid19andcurrenttreatmentstrategy
_version_	1718393563126956032

Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy

Ejemplares similares